REXAHN PHARMACEUTICALS INC DEF14A 6-4-2015

Company

Opus Genetics, Inc.

Filed

April 14, 2015

Period of Report

June 4, 2015

Accession Number

0001140361-15-015351

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →